NEWS RELEASE

Cold Plasma’s Expanding Role in Healthcare Sparks a New Growth Catalyst for Helium

2025-07-11

Technology, Space & Energy

Cold plasma treatment is a powerful, low-heat plasma stream used to treat chronic wounds and eliminate drug-resistant bacteria. Although first identified in 1879, and refined over nearly 150 years of scientific development, the biomedical and industrial applications of cold plasma have only begun to accelerate over the past 50 years - with the most significant breakthroughs emerging in the last decade.

Now, this frontier technology - powered in many of its most advanced forms by helium - is attracting new investor interest. One of the most notable recent milestones came last week, when **Venture Medical announced a direct investment into Plasmacure**, a Dutch firm pioneering cold plasma therapies for chronic, non-healing wounds - a condition affecting more than 2% of the global population. The announcement marks another step towards what many now expect: cold plasma treatments becoming a clinical norm.

This momentum reflects a broader shift. **Recent breakthroughs in using cold plasma to enhance the safety and quality of meat products** have drawn the attention of the U.S. Food & Drug Administration (FDA) - reinforcing the growing potential for cold plasma technology, and helium’s enabling role within it.

What is Cold Plasma?

Cold plasma - also known as non-thermal plasma - is a partially ionized gas that generates powerful reactive species without heat damage. Because it operates at or near room temperature, it’s uniquely suited for use in delicate environments, especially in healthcare and food sterilization.

From treating ulcers and decontaminating surgical tools, to extending shelf life in food or modifying semiconductor surfaces, cold plasma is a non-toxic, waterless, and highly effective alternative to chemical-based processes.

Pulsar Helium Inc
Rua Frederico Arouca, nº 251, 2º frente, 2750-356, Cascais, Portugal
connect@pulsarhelium.com

pulsarhelium.com
pulsarhelum.com
Pulsar Helium Inc

While cold plasma systems can operate using various gases, helium is often preferred in applications that demand precision, safety, and chemical inertness - particularly in the medical, food, and semiconductor sectors. Its low ionization threshold allows for stable plasma generation at lower temperatures, making it ideal for treating heat-sensitive materials and biological tissues. In high-value, precision-critical environments where cold plasma technologies are increasingly being deployed, helium remains the preferred choice.

Market Growth: A Surge in Adoption

According to **Grand View Research**, the global cold plasma technology market size was estimated at USD 2.4 billion in 2024 and is projected to reach USD 3.4 billion by 2030, growing at a CAGR of 6.3% over the forecast period from 2025 to 2030. Adoption is accelerating due to:

- Rising demand for eco-friendly sterilization
- Growth in antibiotic-resistant infections
- Expanding medical applications
- Regulatory momentum supporting non-chemical solutions

Not every cold plasma device uses helium, but its role in enabling the most advanced, high-performance systems cannot be overstated. As cold plasma tech expands globally, so too does the demand for helium as a key enabler of precision, safety, and innovation.

For Pulsar, this marks yet another growth catalyst - aligned with our mission to supply a resource critical to the technologies of tomorrow. Our investors understand this: they're not just backing a commodity - they're backing the future.

As we advance our high-grade helium assets in the U.S. and Greenland - the only company globally with helium projects in both jurisdictions - forward-thinking capital is positioning ahead of the curve, recognising helium as both essential and inevitable. For those just discovering the story, the opportunity is still early.

Pulsar Helium's shares trade on TSXV: PLSR | OTCQB: PSRHF | AIM: PLSR

Disclaimer

This article contains information based on current market conditions and publicly available data. It does not constitute financial advice, and investors should conduct their own due diligence before making any investment decisions.

Marc Farrington
PR & Partnerships
marc@pulsarhelium.com
#PLSRINSIGHTS
Follow us on X